Morgan Stanley Reiterates Overweight on Silence Therapeutics, Maintains $49 Price Target
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Michael Ulz has reiterated an Overweight rating on Silence Therapeutics (NASDAQ:SLN) and maintained a price target of $49.
October 08, 2024 | 4:05 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Morgan Stanley has reiterated its Overweight rating on Silence Therapeutics, maintaining a $49 price target, indicating confidence in the company's potential.
The reiteration of an Overweight rating and a maintained price target of $49 by a major financial institution like Morgan Stanley suggests a positive outlook for Silence Therapeutics. This could lead to increased investor confidence and potential upward movement in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100